Bahena-Casales I, Torres-Cerón A, Laville A, Plata V, Hernández-Cruz A, Bargas J, Pérez-Ortega JE

Language: Spanish
References: 27
Page: 227-242
PDF size: 1005.81 Kb.

ABSTRACT

The therapeutic potential of drugs is determined by biochemical and cellular studies that inform us about their actions on signaling pathways and receptors. However, in some diseases −for example, neurological diseases such as “movement disorders”−, bioassays measure the pharmacological actions by evaluating behavior in animal models of the diseases. There are no bioassays that correlate drug therapeutic actions on living tissue. The neural activity of several neurons can be measured by using calcium imaging on living tissue. Certain parameters of the recorded neuronal activity in vitro reflect the pathological state and the therapeutic actions of specific drugs. There is no integrated system oriented to these bioassays, so different commercial equipment has to be integrated independently with costs about 100,000 USD. We present a prototype of an integral system aimed to perform bioassays in vitro: epifluorescence microscopy with enough quality for the acquisition and quantitative assessment of cell activity recorded in the living tissue with costs around 10 times less −about 10,000 USD−. It allows successfully functional bioassays of potential use in the pharmaceutical industry, research an education.

REFERENCES

1. Fox S.H., Katzenschlager R., Lim S.Y., Ravina B., Seppi K., Coelho M., Poewe W., Rascol O., Goetz C.G., Sampaio C. “The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson’s Disease”., 2013; 28: S2-S41.

2. Gerfen C.R., Surmeier D.J., “Modulation of Striatal Projection Systems by Dopamine”, Annual Review of Neuroscience, Jul. 2011; 34: 441-466.

3. Blesa J., Phani S., Jackson-Lewis V., Przedborski S., “Classic and new animal models of Parkinson’s disease”, J. Biomed. Biotechnol., 2012;2012(845618):1-10.

4. Yadav S., Dixit A., Agrawal S., Singh A., Srivastava G., Singh A.K., Srivastava P.K., Prakash O., Singh M.P., “Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson’s disease pathogenesis”, Mol. Neurobiol., Oct., 2012; 46: 495-512.

5. Patejdl R., Zettl U.K., “Animal models in neurology: drawbacks and opportunities”, Curr. Pharm. Des., 2012;18(29): 4443- 4452.

6. Iderberg H., Francardo V., Pioli E.Y., “Animal models of L-DOPA-induced dyskinesia: an update on the current options”, Neuroscience, Jun 2012; 211: 13- 27.

7. Chou K.L., “In the clinic: Parkinson disease”, Ann. Intern. Med., Nov 2012; 157(9):ITC5-1 - ITC5-16.

8. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., ‘Incidence of Parkinson’s Disease: variation by age, gender, and race/ethnicity”, Am. J. Epidemiol., 2‘003;157(11):1015-1022.

9. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M., “Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030”, Neurology, Jan 2007; 30;68(5):384-386.

10. Braak H., Ghebremedhin E., Rüb U., Bratzke H., Del Tredici K., “Stages in the development of Parkinson’s diseaserelated pathology”, Cell Tissue Res., 2004; 318(1):121-134.

11. Braak H., Bohl J.R., Müller C.M., Rüb U., de Vos R.A., Del Tredici K., “Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered”, Mov. Disord., Dec 2006; 21(12): 2042-2051.

12. Worth P.F., “How to treat Parkinson’s disease in 2013”, Clin. Med., Feb. 2013;13(1): 93-96.

13. Jankovic J., Stacy M., “Medical management of levodopa-associated motor complications in patients with Parkinson’s disease”, CNS Drugs., 2007;21(8): 677-692.

14. Carrillo-Reid L., Tecuapetla F., Tapia D., Hernandez-Cruz A., Galarraga E., Drucker-Colin R., Bargas J., “Encoding network states by striatal cell assemblies”, J. Neurophysiol., 2008; 99(3): 1435-1450.

15. Carrillo-Reid L.,Tecuapetla F., Ibanez- Sandoval O., Hernandez-Cruz A., Galarraga E., Bargas J., “Activation of the cholinergic system endows compositional properties to striatal cell assemblies”, J. Neurophysiol., 2009; 101(2):737-749.

16. Carrillo-Reid L., Hernández-López S., Tapia D., Galarraga E., Bargas J., “Dopaminergic modulation of the striatal microcircuit: receptor-specific configuration of cell assemblies”, J. Neurosci., Oct. 19 2011; 31(42):14972- 14983.

17. Jáidar O., Carrillo-Reid L., Hernández A., Drucker-Colín R., Bargas J., Hernández- Cruz A., “Dynamics of the Parkinsonian striatal microcircuit: entrainment into a dominant network state”, J. Neurosci., Aug 25 2010; 30(34):11326-11336.

18. López-Huerta V.G., Carrillo-Reid L., Galarraga E., Tapia D., Fiordelisio T., Drucker-Colin R., Bargas J., “The balance of striatal feedback transmission is disrupted in a model of parkinsonism”, J. Neurosci., Mar 13 2013; 33(11):4964-4975.

19. Infinity Optical Systems, MicroscopiU The Source for Microscopy Education 2000- 2013, NIKON collaboration. The Florida State University.

20. SiledMR, “LEDs de POTENCIA”, Catálogo Siled 2011.

21. Vulovic M., Rieger B., Van Vliet L.J., Koster A.J., “A toolkit for the characterization of CCD cameras for transmission electron microscopy”, Acta Cryst., 2010; 66(1):97-109.

22. Technical reference manual. Grasshopper Express. Point GreyMR.

23. User Manual Register Reference, Grasshoper GRAS- 50S5M-C, Point GreyMR.

24. Technical application note TAN2007007. Sony R ICX625 CCD Image Sensor Specifications. Point Grey

25. User Manual, LabVIEW R , National InstrumentsMR.

26. Measurements Manual, LabVIEW R , National InstrumentsMR.

27. Erik Cuevas, Daniel Zaldívar, Marco Pérez. Procesamiento digital de imágenes con MATLAB y Simulink. Alfaomega Ra-Ma (México), 2010.